These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 33390852)

  • 1. A Perspective Of Intestinal Immune-Microbiome Interactions In Alcohol-Associated Liver Disease.
    Bruellman R; Llorente C
    Int J Biol Sci; 2021; 17(1):307-327. PubMed ID: 33390852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rice Bran Phenolic Extract Protects against Alcoholic Liver Injury in Mice by Alleviating Intestinal Microbiota Dysbiosis, Barrier Dysfunction, and Liver Inflammation Mediated by the Endotoxin-TLR4-NF-κB Pathway.
    Xiao J; Zhang R; Wu Y; Wu C; Jia X; Dong L; Liu L; Chen Y; Bai Y; Zhang M
    J Agric Food Chem; 2020 Feb; 68(5):1237-1247. PubMed ID: 31722525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut Microbiota and Complications of Liver Disease.
    Acharya C; Bajaj JS
    Gastroenterol Clin North Am; 2017 Mar; 46(1):155-169. PubMed ID: 28164848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice.
    Ferrere G; Wrzosek L; Cailleux F; Turpin W; Puchois V; Spatz M; Ciocan D; Rainteau D; Humbert L; Hugot C; Gaudin F; Noordine ML; Robert V; Berrebi D; Thomas M; Naveau S; Perlemuter G; Cassard AM
    J Hepatol; 2017 Apr; 66(4):806-815. PubMed ID: 27890791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.
    Maccioni L; Leclercq IA; Schnabl B; Stärkel P
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiome as a therapeutic target in alcohol-related liver disease.
    Sarin SK; Pande A; Schnabl B
    J Hepatol; 2019 Feb; 70(2):260-272. PubMed ID: 30658727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lychee (Litchi chinensis Sonn.) Pulp Phenolic Extract Provides Protection against Alcoholic Liver Injury in Mice by Alleviating Intestinal Microbiota Dysbiosis, Intestinal Barrier Dysfunction, and Liver Inflammation.
    Xiao J; Zhang R; Zhou Q; Liu L; Huang F; Deng Y; Ma Y; Wei Z; Tang X; Zhang M
    J Agric Food Chem; 2017 Nov; 65(44):9675-9684. PubMed ID: 29041775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alcohol, liver disease and the gut microbiota.
    Bajaj JS
    Nat Rev Gastroenterol Hepatol; 2019 Apr; 16(4):235-246. PubMed ID: 30643227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbiota-based treatments in alcoholic liver disease.
    Sung H; Kim SW; Hong M; Suk KT
    World J Gastroenterol; 2016 Aug; 22(29):6673-82. PubMed ID: 27547010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
    Woodhouse CA; Patel VC; Singanayagam A; Shawcross DL
    Aliment Pharmacol Ther; 2018 Jan; 47(2):192-202. PubMed ID: 29083037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From intestinal dysbiosis to alcohol-associated liver disease.
    Mendes BG; Schnabl B
    Clin Mol Hepatol; 2020 Oct; 26(4):595-605. PubMed ID: 32911590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases.
    Sharma SP; Suk KT; Kim DJ
    World J Gastroenterol; 2021 Oct; 27(37):6161-6179. PubMed ID: 34712025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin A and liver diseases.
    Inamine T; Schnabl B
    J Gastroenterol; 2018 Jun; 53(6):691-700. PubMed ID: 29075899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partners in Leaky Gut Syndrome: Intestinal Dysbiosis and Autoimmunity.
    Kinashi Y; Hase K
    Front Immunol; 2021; 12():673708. PubMed ID: 33968085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.
    Chopyk DM; Grakoui A
    Gastroenterology; 2020 Sep; 159(3):849-863. PubMed ID: 32569766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the gut microbiota to treat alcoholic liver diseases: evidence and promises.
    Leclercq S; de Timary P; Stärkel P
    Acta Gastroenterol Belg; 2020; 83(4):616-621. PubMed ID: 33321019
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Li H; Shi J; Zhao L; Guan J; Liu F; Huo G; Li B
    J Agric Food Chem; 2021 Jan; 69(1):183-197. PubMed ID: 33353302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.